Acknowledgements The research was supported in part by the National Institutes of Health (R01-GM115622 and R01-CA207701 to J.W., R01-AG045183, R01-AT009050, R21-EB022302 and DP1-DK113644 to M.C.W., R01-GM120033 to M.M.-S., R01-NS100893 to M.X.), the Welch Foundation (Q-1912 to M.C.W.), Cancer Prevention and Research Institute of Texas (CPRIT R1104 to J.W., RP130573 to M.M.-S.), Whitehall Foundation Research Grant (2015-05-54 to M.X.), the Curtis Hankamer Basic Research Fund at Baylor College of Medicine (to M.X.), Caroline DeLuca Scholarship (to M.X.), the United States Department of Agriculture, Agricultural Research Service through Cooperative Agreement Number 58-6250-0-008 (to N.C.), the IDDRC Microscopy Core (P30HD024064 and 1U54 HD083092 Intellectual and Developmental Disabilities Research Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development), the Optical Imaging and Vital Microscopy core, and the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (AI036211, CA125123, and RR024574) and the expert assistance of Joel M

We have already discussed clever marketing ploys, and this is no different
SBIRs allow private consultants to be a part of the proposal however STTRs do not
For instance, some individuals may experience side effects or have an immune system response that causes them to feel unwell temporarily
The TB-500 Identity Problem This is the most important scientific issue in any Wolverine Stack article
the technical problem underlying the present invention is to provide BPC peptides in more stable form and a diagnostic and/or pharmaceutical composition comprising BPC peptides exhibiting improved stability and at least the same pharmaceutical activities as the BPC peptides themselves